Jonathan Milner, co-founder of Abcam, offers a masterclass in building successful life science starts-ups, based on his experience with over 40 companies and three Tech IPOs on the London AIM Stock Exchange.
- Mon 22nd Jan 2018
Jonathan will be looking at the bigger picture trends and breakthroughs in life sciences and then explain how he is trying to translate this exciting science into businesses. His particular areas of interest include stem cell technology; new approaches to drug discovery; genomics and proteomics big data; and diseases of ageing and the ageing process.
Jonathan cofounded Abcam when working as a postdoctoral researcher studying the newly discovered breast cancer protein BRCA2 in Kouzarides' Cambridge University laboratory. Now a listed e-commerce company providing antibodies and other protein research tools to a global market, it encourages and publishes product reviews and ratings submitted by customers.
Horizon Discovery designs and engineers genetically modified cells, applying them in research and clinical applications that advance human health.
Dr. Jonathan Milner, Deputy Chairman, Abcam plc
The subject wasn't what I was expecting, given the title of the talk. However it was very well delivered, interesting and entertaining.
Very interesting talk but not addressed to the title published. I preferred the talk that was give but a bit concerned that some might have come and been disappointed.
Beautiful lecture style I would use it to teach students how to present
Outstanding presentation. Cannot escape the impression though that science has still not established cause and effect in most areas. It resembles the era when Mendel, Darwin and many others were trying to establish what Heredity was causing which ultimately resulted in the breakthrough of establishing the structure of DNA by Rosalind Franklin, Watson and Crick. And since then we have uncovered much more about the workings of the cells, but we are still traipsing around.
Not what was advertised but fascinating and thought provoking anyway, A little long and the speaker largely took pains to explain technical terms but there were parts where the jargon took over,and unfortunately at some of the key parts. It would be great to get him back to talk about biotech companies as he is such an enthusiastic and energetic speaker.
The lecture will be preceded by a short presentation from a CSAR PhD Student Award winner
Stabilising Omomyc - a new cancer drug